Calcaterra and colleagues provide a timely narrative review on epicardial adipose tissue (EAT) as an imaging marker of cardiometabolic risk and a potentially modifiable therapeutic target [1]. Yet the translational promise implied by “earlier prediction” will be realised only if EAT assessment can move beyond compelling associations to reproducible measurement, incremental clinical value over established risk markers, and actionable pathways that improve outcomes rather than merely tracking correlated biology.
